2026-04-13T02:05:29Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/131062025-10-24T10:20:26Zcom_2072_378070com_2072_378040col_2072_378092

00925njm 22002777a 4500 dc Passiglia, Francesco author Listi, Angela author Bironzo, Paolo author Merlini, Alessandra author Benso, Federica author napoli, francesca author FELIP, ENRIQUETA author 2025-05-19T06:29:30Z 2025-05-19T06:29:30Z 2024 2025-05 Proves de biomarcadors; Càncer de pulmó; Teràpia dirigida Biomarker testing; Lung cancer; Targeted therapy Pruebas de biomarcadores; Cáncer de pulmón; Terapia dirigida Introduction The advocacy Women Against Lung Cancer in Europe (WALCE) promoted the European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA) and provided a free-of-charge molecular profiling platform for NSCLC sample characterization with the aim of increasing the detection of targetable drivers and improving patients’ access to clinical trials in Europe. Methods From January 2021 to December 2023, 20 centers located at five different European countries (Greece, Slovenia, Romania, Albania, and Italy) joined EPROPA, with 555 patients with advanced NSCLC registered to the program. Anonymized patients’ clinical-pathological data were shared through the EPROPA web platform and tissue samples were collected at the Molecular Pathology Unit of the Reference Center (University of Turin) for molecular analyses. A comprehensive genomic profiling by a targeted next-generation sequencing approach has been performed and molecular reports have been discussed within the molecular tumor board to assess patients’ eligibility for clinical trials. Results The average turnaround time was eight days, with only 30 out of 555 tissue samples (6%) not suitable for molecular analysis. In the 525 analyzed samples, a total of 570 molecular alterations have been identified, including 264 pathogenic targetable oncogenic alterations and 113 cases with co-occurring mutations. A total of 18 molecular alterations with potential germline and hereditary cancer syndrome implications have been reported. The identification of a clinical trial was considered for 205 patients. After molecular tumor board discussion, 30 patients were enrolled and treated in clinical studies available in Europe. Survival outcomes were significantly improved in patients with targetable molecular alterations receiving a matched targeted therapy. Conclusion This data confirmed the feasibility and usefulness of the program in the real-world practice scenario, supporting the implementation of next-generation sequencing–based molecular characterization of NSCLC samples, to reduce the unequal access to tests, drugs, and clinical trials in Europe. This work was supported by an unrestricted educational grant by AstraZeneca, Amgen, BeiGene, Blueprint Medicines, Boeringher Ingelheim, Gilead, Incyte, Eli Lilly, Merck, MSD, Novartis, Pfizer, Roche, Sanofi, Thermo Fisher Scientific with no role in study design, data collection, data analysis, data interpretation and report writing. To the Women Against Lung Cancer Europe (WALCE) Advocacy Group, Francesca Arizio, Cristina Destro, Ewelina Smzytke (LuCE), Angela Dicorato (SC Oncology – ASU GI, Trieste, Italy), Ravzan Curca (Spitalul Juedetean de Urgenta, Alba Iulia, Romania) and Daniela Elvira Sirbu (Centrul de Oncologie Oncohelp, Timisoara, Romania). http://hdl.handle.net/11351/13106 Anomalies cromosòmiques Medicina personalitzada Pulmons - Càncer - Aspectes genètics PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation DISEASES::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung Other subheadings::Other subheadings::Other subheadings::/genetics ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Precision Medicine FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas Otros calificadores::Otros calificadores::Otros calificadores::/genética TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::medicina de precisión Actionable NSCLC Mutation Identification by Comprehensive Genomic Profiling for Clinical Trial Enrollment: The European Program for the Routine Testing of Patients With Advanced Lung Cancer (EPROPA)